BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Protecting Rare Plants with a Monmouth Scientific Class 2 Biological Safety Cabinet November 4, 2025 What’s the Difference Between Type 1 and Type 2 Diabetes? September 12, 2024 Dogs offer more emotional support than most people, study finds April 22, 2025